| Trial ID: | L7314 |
| Source ID: | NCT00604253
|
| Associated Drug: |
Insulin Detemir
|
| Title: |
Efficacy and Safety of Insulin Detemir in Type 2 Diabetes Inadequately Controlled on OHA Therapy Alone
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: insulin detemir|DRUG: insulin NPH
|
| Outcome Measures: |
Primary: HbA1c, after 36 weeks of treatment | Secondary: Plasma glucose profiles|Incidence of hypoglycaemic episodes|Adverse events|Insulin antibodies
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE3
|
| Enrollment: |
362
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-12
|
| Completion Date: |
2005-05
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-27
|
| Locations: |
Novo Nordisk Investigational Site, Tokyo, 1000005, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT00604253
|
